Ligand以 2300万美元从 Sydnexis获得 Santen旗下 Ryjunea®的特许权使用费及里程碑权益-动脉网

Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million

GlobeNewswire 等信源发布 2026-09-22 11:00



可切换为仅中文







Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients

Ryjunea 是首个且唯一获欧盟委员会和英国药品和健康产品管理局（MHRA）批准、用于延缓儿童患者近视进展的药物治疗方案。

Ligand will receive a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and Africa

Ligand 将根据 Ryjunea 在欧洲、中东和非洲地区的净销售额，收取分级计算的 royalty，费率从低双位数百分比至高十几百分比不等。

JUPITER, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has acquired an ascending tiered royalty interest in Santen Pharmaceutical Co., Ltd.’s (“Santen”) Ryjunea® from Sydnexis, Inc. (“Sydnexis”) for a $23 million upfront payment.

佛罗里达州朱庇特，2026年9月22日（环球新闻社）——Ligand Pharmaceuticals Incorporated（纳斯达克股票代码：LGND）今日宣布，已通过向Sydnexis, Inc.（“Sydnexis”）支付2,300万美元的预付款，收购了参天制药株式会社（“参天”）旗下Ryjunea®的分级递增 royalty 权益。

Ryjunea is a once-nightly, low-dose atropine eye drop designed to slow progression of myopia (commonly known as nearsightedness) in pediatric patients. Treatment may be indicated in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to -6.0 D. The product uses a standardized 0.01% formulation of atropine with deuterated water designed to improve efficacy, comfort, and stability in the pediatric population.

Ryjunea 是一种每晚一次、低剂量的阿托品滴眼液，旨在延缓儿童患者近视（俗称近视眼）的进展。该疗法适用于年龄在3至14岁、每年进展速率达到0.5屈光度（D）或以上、且近视程度在-0.5 D至-6.0 D之间的儿童。该产品采用标准化的0.01%阿托品配方，并结合重水，旨在提高在儿童人群中的疗效、舒适度和稳定性。

Santen licensed rights to Ryjunea in Europe, the Middle East, and Africa (“EMEA”) from Sydnexis in 2021. Ryjunea was approved by the European Commission in June 2025 and the UK Medicines and Healthcare products Regulatory Agency (“MHRA”) in October 2025..

参天制药于2021年从Sydnexis公司获得了Ryjunea在欧洲、中东和非洲（“EMEA”）地区的授权许可。Ryjunea于2025年6月获得欧盟委员会批准，并于2025年10月获得英国药品和保健品监管局（“MHRA”）批准。

“Ryjunea represents the type of differentiated asset we look to add to our expanding royalty portfolio. As the first and only approved pharmacological treatment in the European Union and the United Kingdom for slowing pediatric myopia, Ryjunea addresses a significant market need by providing a stable, clinically validated, and GMP manufactured option to manage this chronic condition.

“Ryjunea 代表了我们希望纳入不断扩大的特许权使用费投资组合中的差异化资产类型。作为欧盟和英国首款且唯一获批用于延缓儿童近视进展的药物疗法，Ryjunea 通过提供一种稳定、经临床验证且符合药品生产质量管理规范（GMP）的生产选项来管理这一慢性疾病，从而满足重大的市场需求。”

Santen has built a strong ophthalmology presence across Europe and has identified myopia as a key strategic growth area, giving us confidence in the product’s long-term commercial potential,” said Todd Davis, CEO of Ligand..

“参天制药已在欧洲建立起强大的眼科业务布局，并将近视防控确定为关键的战略增长领域，这使我们对该产品长期的商业潜力充满信心。”Ligand首席执行官Todd Davis表示。

Under the terms of the agreement, Ligand will pay $23 million upfront to acquire a 100% interest in certain payments and related rights under Sydnexis’s existing license agreement with Santen. The acquired payment rights include a tiered low-double-digit to high-teens royalty on Ryjunea net sales in EMEA, as well as certain milestone payments.

根据协议条款，Ligand将预付2300万美元，以收购Sydnexis与Santen现有许可协议项下某些付款及相关权利的100%权益。所收购的付款权利包括基于Ryjunea在EMEA地区净销售额的分层低双位数至接近20%的特许权使用费，以及某些里程碑付款。

Sydnexis retains commercial rights to Ryjunea in the U.S. and all other non-Santen licensed territories..

Sydnexis 保留 Ryjunea 在美国及所有其他非参天授权地区的商业权利。

Myopia is a condition in which the focal point for distant objects is in front of the retina, instead of directly on it, and results in vision loss. It has been reported that, in addition to affecting patient quality of life, the progression to “high myopia” increases the risk of severe ocular complications that can lead to permanent visual impairment or blindness.

近视是一种远处物体的焦点落在视网膜前方而非直接落在视网膜上的状况，会导致视力下降。据报道，除了影响患者的生活质量外，进展为“高度近视”还会增加严重眼部并发症的风险，这些并发症可能导致永久性视力损害或失明。

In Europe, approximately 1 in 3 children and adolescents are projected to be affected by myopia by 2050,.

到2050年，欧洲预计将有约三分之一的儿童和青少年受到近视影响。

and Santen estimates 14 million patients were affected in 2025.

参天制药估计，2025年有1400万患者受到影响。

McDermott Will & Schulte LLP and Cooley LLP served as legal advisors to Ligand.

McDermott Will & Schulte LLP 和 Cooley LLP 担任了 Ligand 的法律顾问。

About Ligand

关于配体

Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets.

Ligand 是一家领先的特许权使用费聚合商，与生物制药公司合作，为后期临床开发项目提供资金并推动其进展。Ligand 拥有并管理着行业内规模最大、最多样化的生物制药特许权使用费组合之一，在200多个处于开发和商业化阶段的资产中拥有经济权益。

Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network.

Ligand 通过换取长期经济利益，为高价值项目提供资金支持，使资本与临床及商业成功保持一致。Ligand 的特许权使用费组合旨在通过广泛的治疗资产组合，提供稳定且可预测的收入流。此外，Ligand 还向其全球合作伙伴网络授权其专有技术 Captisol® 和 NITRICIL™，以支持药物开发和制剂研究。

For more information, visit .

更多信息，请访问。

www.ligand.com

or follow Ligand on

或在以下平台关注 Ligand

and

和

领英

。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters.

本新闻稿包含前瞻性陈述，旨在符合1995年美国《私人证券诉讼改革法》下的“安全港”条款。前瞻性陈述通常伴有诸如“相信”、“可能”、“将”、“估计”、“继续”、“预期”、“打算”、“期望”、“应该”、“会”、“计划”、“预测”、“潜在”、“寻求”、“未来”、“展望”等词语，以及类似表达，这些词语用于预测或指示未来事件或趋势，或不属于历史事实的陈述。

These forward-looking statements include, but are not limited to, statements relating to Ryjunea’s commercial potential; the size and growth of the market for treatments for pediatric myopia; Santen’s commercialization, market access and other activities relating to Ryjunea; future sales of Ryjunea; Ligand’s expected receipt of royalties, reimbursement approval milestones and sales milestones relating to Ryjunea and Ligand’s royalty portfolio strategy and expected revenue characteristics..

这些前瞻性陈述包括但不限于，有关Ryjunea的商业潜力；儿童近视治疗市场的规模和增长；参天制药（Santen）与Ryjunea相关的商业化、市场准入及其他活动；Ryjunea的未来销售；Ligand预期收到的特许权使用费、报销批准里程碑和销售里程碑，以及Ligand的特许权使用费组合策略和预期收入特征。

These statements are based on various assumptions and on the current expectations of Ligand’s management and are not predictions of actual performance. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions, many of which are beyond Ligand’s control. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

这些陈述基于各种假设以及Ligand管理层的当前预期，并非对实际业绩的预测。实际事件和情况难以或无法预测，可能与假设存在差异，其中许多假设超出Ligand的控制范围。这些前瞻性陈述受多种风险和不确定性的影响，可能导致实际结果与这些陈述所表达或暗示的结果存在重大差异。

Risks and uncertainties include, among other things, Ligand’s reliance on Santen and other third parties for the commercialization, manufacture and sale of Ryjunea and for the payment of royalties and milestones; the possibility that Ryjunea sales may be lower than expected; the timing, availability and scope of regulatory, pricing and reimbursement approvals; competition from compounded atropine, optical treatments and existing or future pharmaceutical products; changes in market acceptance, prescribing practices or treatment guidelines; the possibility that applicable royalty rates may be reduced under the underlying license agreement; challenges to, or the expiration or invalidation of, intellectual property rights relating to Ryjunea; and the other risk factors discussed under the heading “Item 1A.

风险和不确定性包括但不限于：Ligand 依赖 Santen 及其他第三方进行 Ryjunea 的商业化、生产和销售，以及支付特许权使用费和里程碑付款；Ryjunea 的销售额可能低于预期；监管、定价和报销审批的时间、可用性和范围；来自复方阿托品、光学疗法以及现有或未来药品的竞争；市场接受度、处方实践或治疗指南的变化；根据基础许可协议，适用的特许权使用费率可能被降低；与 Ryjunea 相关的知识产权受到挑战、到期或被宣告无效；以及在“第 1A 项”标题下讨论的其他风险因素。

Risk Factors” in the Ligand’s Annual Report on Form 10-K for the year ended December 31, 2025 (filed February 27, 2026) and Quarterly Reports on Form 10-Q for the quarter ended March 31, 2026 (filed with the SEC on May 8, 2026) and for the quarter ended June 30, 2026 (filed with the SEC on August 7, 2026).

“风险因素”部分，见Ligand公司截至2025年12月31日止年度的10-K表年度报告（于2026年2月27日提交），以及截至2026年3月31日止季度（于2026年5月8日向美国证券交易委员会提交）和截至2026年6月30日止季度（于2026年8月7日向美国证券交易委员会提交）的10-Q表季度报告。

Ligand cautions against placing undue reliance on these forward-looking statements, which speak only as of the date of this press release, and undertakes no obligation to update any forward-.

Ligand 提醒不要过度依赖这些前瞻性陈述，这些陈述仅反映本新闻稿发布之日的情况，且公司不承担更新任何前瞻性陈述的义务。

Contacts

联系人

Investors:

投资者：

Melanie Herman

梅兰妮·赫尔曼

investors@ligand.com

(858) 550-7761

Media:

媒体：

Kellie Walsh